Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab or Glofitamab + CELMoDs in B-Cell NHL
NCT05169515Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2022
- Primary completion
- Aug 2029
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of mosunetuzumab, glofitamab, iberdomide and golcadomide in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Roche. Primary endpoints: Dose-Limiting Toxicities at 90 days, Adverse Events at 90 days and 2 more. Started Oct 2022; status: active, not recruiting.
02
Drugs
mosunetuzumabglofitamabiberdomidegolcadomide
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05169515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169515.